Zhengye Biotechnology Holding (ZYBT) Liabilities and Shareholders Equity (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $61.5 million the latest figure, recorded in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 10.38% year-over-year to $61.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $269.4 million (changed N/A YoY) and the FY2025 annual result came in at $61.5 million, down 8.93% from the prior year.
• Liabilities and Shareholders Equity slipped to $61.5 million in Q4 2025 per ZYBT's latest filing, from $69.8 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ZYBT reached as high as $69.8 million in Q2 2025 and fell as low as $61.5 million in Q4 2025.
• A 3-year average of $67.4 million and a median of $69.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity retreated 1.1% — and 2025, when it fell 10.38%.
• Year by year, Liabilities and Shareholders Equity stood at $69.4 million in 2023, then fell by 1.1% to $68.7 million in 2024, then slipped by 10.38% to $61.5 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $61.5 million, $69.8 million, and $68.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.